Corvus Pharmaceuticals, Inc. (CRVS) — Financial statements
Income statement, balance sheet, and cash flow for Corvus Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 34↑73.9% | 19↑17.3% | 17↓32.5% | 24↓16.0% | 29 | |
| General & Administrative Expenses | 9↑13.3% | 8↑18.6% | 7↓15.0% | 8↓14.9% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑13.3% | 8↑18.6% | 7↓15.0% | 8↓14.9% | 10 | |
| Other Expenses | -0.11 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 43↑55.6% | 28↑17.7% | 23↓28.1% | 33↓15.7% | 39 | |
| Total Costs & Expenses | 43↑56.0% | 28↑17.7% | 23↓28.1% | 33↓15.7% | 39 | |
| Operating Results | ||||||
| Operating Income | -43↓56.0% | -28↓17.7% | -23↑28.1% | -33↑15.7% | -39 | |
| Depreciation & Amortization | 0.11↑23.5% | 0.09↓43.7% | 0.15↓58.9% | 0.37↓20.2% | 0.46 | |
| EBITDA | -43↓56.5% | -27↓18.1% | -23↑27.8% | -32↑15.6% | -38 | |
| EBIT | -43↓56.0% | -28↓17.7% | -23↑28.1% | -33↑15.7% | -39 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑37.3% | 2↑15.2% | 2↑142.2% | 0.65↑4460.0% | -0.02 | |
| Interest Income | 3↑37.3% | 2↑15.2% | 2↑142.2% | 0.65 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 28↑179.7% | -35↓859.3% | -4↑58.6% | -9↓89.6% | -5 | |
| Income Before Tax | -15↑75.5% | -62↓130.5% | -27↑34.6% | -41↑4.5% | -43 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -15↑75.5% | -62↓130.5% | -27↑34.6% | -41↑4.5% | -43 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -15↑75.5% | -62↓130.5% | -27↑34.6% | -41↑4.5% | -43 | |
| Bottom-Line Net Income | -42↑31.9% | -62↓130.5% | -27↑34.6% | -41↑4.5% | -43 | |
| EPS (Basic) | -0.19↑81.4% | -1.02↓81.2% | -0.56↑36.8% | -0.89↑13.6% | -1.03 | |
| EPS (Diluted) | -0.53↑48.0% | -1.02↓81.2% | -0.56↑36.8% | -0.89↑13.6% | -1.03 | |
| Weighted Average Shares | 79↑29.5% | 61↑27.0% | 48↑3.2% | 47↑11.2% | 42 | |
| Weighted Average Diluted Shares | 80↑30.8% | 61↑27.0% | 48↑3.2% | 47↑11.2% | 42 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.